PAG
MCRB icon

Private Advisor Group’s Seres Therapeutics MCRB Stock Holding History

Private Advisor Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-140
Closed -$13K – 2672
2020
Q2 		$13K Buy
+140
New +$12.3K ﹤0.01% 2801

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Private Advisor Group's MCRB Position: Q3 2020 in Review

Private Advisor Group sold out of Seres Therapeutics (MCRB) in Q3 2020, closing a stake of 140 shares — an estimated $13K sold.

Private Advisor Group first reported a position in MCRB in Q2 2020 and held it in 1 quarter. The position peaked at $13K in Q2 2020. 113 funds tracked by Wall St. Rank hold MCRB as of Q3 2020.

  • Private Advisor Group reported no remaining Seres Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 140 Seres Therapeutics shares in Q3 2020, an estimated $13K.
  • Private Advisor Group first reported a position in Seres Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Seres Therapeutics position peaked at $13K in Q2 2020.
  • 113 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.